Yigal Arnon & Co. in cooperation with IATI (Israel Advanced Technology Industries) invite Hi-Tech & Life Science Start-ups to join us in the event: “The Ins-and-Outs of the Due Diligence Process in Investment Transactions”, October 23, 2013, Yigal Arnon & Co. offices.
Advocates Barry Levenfeld, Harry Kirsh, Yuval Shalhevet, Zohar Nevo and Noam Enk represents the winning bidding consortium, consisting of Johnson & Johnson, Takeda Pharmaceuticals (the first Japanese Pharmaceutical Company to invest in Israel) and the healthcare fund OrbiMed Israel, for the establishment of an OCS-supported biotechnological incubator intended to encourage the creation and support of pharmaceutical and medical device companies.
Advocates Adrian Daniels, Guy Lachmann and Avi Anouchi represented Enigma Information Systems Ltd. in its acquisition by Parametric Technology Israel Ltd., a subsidiary of PTC, Inc. (NASDAQ: PMTC), for an approximate amount of US$ 10 million. The transaction was structured as a reverse triangular merger and required advising on many cross-border legal issues.
Yigal Arnon & Co. sponsored the Tel Aviv 100 Summit Conference at the David Intercontinental Hotel on July 2, 2013.
Adv. Gil Oren lectured on "Debt Arrangement".
Yigal Arnon & Co., in cooperation with IATI, is hosting a Professional Session for start-ups and entrepreneurs on Thursday, July 4, 2013 at 19:00, at TECHLOFT, Tel Aviv
Advocates Shiri Shaham, Simon Weintraub and Noam Meir represented and served as Israeli counsel to JP Morgan, HSBC Bank PLC and Citibank, in a $300 million bridge financing transaction of the Tamar Project Partnership and specifically to Delek Drilling LP and Avner Oil Exploration LP, towards the continued financing of the development of the Israeli offshore natural gas exploration with respect to the Tamar project and also to fund other offshore natural gas exploration projects.
Advocates David Schapiro and Eliran Furman represented Royal Bank of Canada in a sale of its shareholdings in Tamir Fishman & Co. to Mr. Eldad Tamir – one of the company's largest shareholders. The transaction included the acquisition by Eldad Tamir of most of the remaining shares owned by other shareholders as well.
Articled published in "Globes" newspaper, May, 2013.
Advs. Barry Levenfeld, Eric Spindel, Avigail Frisch and Noam Enk represented Aegis for Alcobra Ltd.'s initial public offering on Nasdaq. Alcobra Ltd., headquartered in Israel, is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug to treat Attention Deficit Hyperactivity Disorder.